| الوصف: |
Yi Sun,1 Wenqiang Li,2 Ai-Jie Li,2 Huichao Su,1 Jinbo Yue,1,3 Jinming Yu1,31Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong 250117, People’s Republic of China; 2Department of Radiation Oncology, Weifang Medical University, Weifang, Shandong, 261053, People’s Republic of China; 3School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, Jinan, Shandong, 250000, People’s Republic of ChinaPurpose: We sought to examine the role of pretreatment systemic immune-inflammation index (SII) in hormone receptor-negative, human epidermal growth factor receptor 2+ (HER2+) breast cancer patients.Patients and methods: 155 HER2+ patients treated in our hospital from September 3, 2002, to September 21, 2012, were retrospectively enrolled. SII was established as neutrophil x platelet/lymphocyte counts. The median value of SII was used as cut-off value. We used the Kaplan-Meier method to evaluate the overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS). To comparatively evaluate the survival rates between patients from two groups, we used the log-rank test. For identifying independent factors of prognosis, we used the Cox regression model, applying multivariate statistics.Results: Analyses show that HER2+ patients with high and low SII had median DFS of 15.1 and 31.5months, respectively (P |
PDF full text from Publisher